Genetic Technologies
Genetic Technologies Gets Nasdaq Delisting Warning
The Australian genomic testing company said that its American Depositary Shares have failed to meet the Nasdaq's minimum bid price requirement for continued listing.
Genetic Technologies Lab Gets Regulatory Approvals in US, Australia
The lab has received NATA accreditation and CLIA certification, enabling the launch of the company's multi-disease risk assessment test in Australia and the US.
In Brief This Week: Quest Diagnostics, Beckman Coulter, Thermo Fisher Scientific, Diadem, and More
News items for the in vitro diagnostics industry for the week of Jan. 17, 2022.
In Brief This Week: PerkinElmer, Fujirebio Europe, Exagen, Genetic Technologies, and More
News items for the in vitro diagnostics industry for the week of Oct. 25, 2021.
Genetic Technologies, WashU Team up to Study Breast Cancer Risk in Woman of African Descent
The Australian company is working with the Institute for Public Health in St. Louis to expand the predictive capability of its GeneType breast cancer risk test.
May 26, 2020
Genetic Technologies Prices $8M Public Offering
Apr 20, 2020
Genetic Technologies Prices $1.4M Direct Offering
Apr 1, 2020